AstraZeneca plc vs United States Oil ETF — how do they compare? AstraZeneca plc trades at $158.67 (market cap $248.14B), while United States Oil ETF trades at $127.25. The key difference: AstraZeneca plc pays a 2.01% dividend while United States Oil ETF pays none, and United States Oil ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | USO | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | — |
52-Week High | $209.48 | $152.96 |
52-Week Low | $147.06 | $66.17 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
USO trades at $127.36, up 1.14% with bullish technical signals from moving averages. The stock faces mixed sentiment as oil markets balance supply disruptions from Middle East tensions against OPEC's downward demand revisions. Technical indicators show strong momentum with ADX signaling trend strength while RSI remains neutral, suggesting room for further movement.
The outlook remains volatile with geopolitical risks driving price action. Upside potential exists if Middle East supply constraints persist, but demand destruction concerns and inventory builds present headwinds. Investors should monitor Strait of Hormuz developments and EIA inventory data for directional catalysts.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →